Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lara Wine Lee

Pediatric Dermatology Charleston, SC Medical Doctor

NPI 1710187224 CMS profile 611109

171 Ashley Ave, Charleston, SC 29425

Open in the dashboard

General payments

$173,587

207 records reported · program years 2019–2025

Research payments

$37,786

Paid to them · 37 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,558,435 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Lara Wine Lee of Charleston, SC is reported in the CMS Open Payments database as having received $173,587 across 207 general payments and $37,786 in research payments paid to them. Separately, studies naming them as principal investigator received $7,558,435 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Pediatric Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $81,199 61
2024 General $34,095 41
2024 Research $12,905 6
2023 General $19,319 26
2023 Research $7,595 13
2022 General $14,890 28
2022 Research $7,089 13
2021 General $2,583 3
2021 Research $2,103 3
2020 General $13,281 15
2020 Research $314 1
2019 General $8,219 33
2019 Research $7,781 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lara Wine Lee
  • Pediatric Dermatology median
  • Middle half of Pediatric Dermatology
  • National median

In program year 2025, general payments to Lara Wine Lee were reported at $81,199. Among 172 Pediatric Dermatology profiles paid that year, the median was $302 and the middle half received between $110 and $2,128.

Show as a table
Year Lara Wine Lee Pediatric Dermatology median Middle half National median
2019 $8,219 $280 $89–$1,853 $163
2020 $13,281 $263 $71–$2,376 $114
2021 $2,583 $227 $69–$1,800 $132
2022 $14,890 $289 $69–$1,516 $149
2023 $19,319 $537 $114–$3,255 $160
2024 $34,095 $437 $114–$2,693 $164
2025 $81,199 $302 $110–$2,128 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Chiesi USA, Inc. $54,051 31 payments
  2. Krystal Biotech Inc $44,690 44 payments
  3. Lilly USA, LLC $16,365 37 payments
  4. Regeneron Pharmaceuticals, Inc. $13,157 17 payments
  5. Genzyme Corporation $10,990 10 payments
  6. AbbVie, Inc. $7,493 14 payments
  7. Amryt Pharma Holdings Ltd $7,464 9 payments
  8. Eli Lilly and Company $5,233 5 payments
  9. E.R. Squibb & Sons, L.L.C. $3,750 1 payment
  10. Novartis Pharmaceuticals Corporation $3,356 10 payments
  11. Other $7,038 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $63,324 22 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47,586 14 payments
  3. Travel and Lodging $31,117 55 payments
  4. Honoraria $26,257 6 payments
  5. Food and Beverage $5,247 104 payments
  6. Education $57 6 payments
Products named General payments · program years 2019–2025
  1. VYJUVEK $44,690 44 payments
  2. FILSUVEZ $32,800 25 payments
  3. DUPIXENT Inflammation And Immunology $13,157 17 payments
  4. EBGLYSS $7,973 7 payments
  5. OLUMIANT $5,200 2 payments
  6. SOTYKTU $3,750 1 payment
  7. COSENTYX $3,058 6 payments
  8. SKYRIZI $3,054 2 payments
  9. ZEVASKYN $3,025 2 payments
  10. DUPIXENT Immunology $2,746 7 payments
  11. Other $4,252 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $29,626 33 payments
  2. Eli Lilly and Company $8,160 4 payments

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Dermatology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record